Doximity Shares Tumble 24% as BofA Cuts Price Target to $38 Amid Earnings‑driven Downgrade Wave

Why It Matters

The sharp downgrade wave around Doximity highlights the growing pressure on digital‑health firms to deliver tangible returns from AI investments. As investors demand clearer pathways to revenue growth, companies that cannot demonstrate near‑term monetization may face steep valuation cuts, influencing capital allocation across the sector. Moreover, Doximity’s record free‑cash‑flow quarter shows that profitability can coexist with heavy AI spend, but the market is skeptical about the timing and scale of future upside. For earnings‑call watchers, the Doximity episode illustrates how a single earnings release can trigger a cascade of analyst actions, reshaping market expectations in minutes. It also serves as a cautionary tale for firms that announce ambitious AI roadmaps without accompanying revenue guidance that meets or exceeds consensus expectations.

Key Takeaways

• BofA cuts Doximity price target to $38 from $47, maintaining a buy rating
• Shares fell ~24% on May 14, extending a >45% YTD decline
• Fiscal Q4 2026 revenue $145.4M (+5% YoY) but FY2027 guidance $664M‑$676M (3%‑5% growth) missed consensus
• Adjusted EPS forecast $0.26 vs. $0.28 consensus; free cash flow hit $107M record
• More than 10 Wall Street firms downgraded or cut targets, including Jefferies, Wells Fargo, and Baird

Pulse Analysis

Doximity’s earnings call laid bare a classic growth‑versus‑profitability dilemma that is now playing out across the digital‑health landscape. The company’s decision to label fiscal 2027 an "AI investment year" signals a strategic pivot toward high‑margin, data‑driven services, yet the market’s reaction suggests investors are unwilling to finance a long runway without clearer near‑term revenue upside. BofA’s valuation downgrade—anchored in a lower EV/EBITDA multiple and a 12% free‑cash‑flow yield—reflects a broader shift toward cash‑flow‑centric metrics in a sector traditionally driven by user‑growth narratives.

Historically, digital‑health firms that have successfully integrated AI have done so by pairing technology rollouts with incremental, billable services—think telehealth platforms that monetize per‑visit fees. Doximity’s current model, which leans heavily on a free‑to‑use professional network, may require a more aggressive monetization strategy to justify its AI spend. The downgrade wave also underscores the power of sell‑side consensus: once a leading house like BofA signals heightened execution risk, peers quickly follow, amplifying price pressure.

Looking ahead, Doximity must demonstrate that its AI investments translate into measurable revenue lifts, perhaps through new subscription tiers, data‑licensing deals, or integrated clinical workflow solutions. If it can convert its record $107 million free‑cash‑flow quarter into a sustainable cash‑generation engine, the stock could rebound. Failing that, the current valuation may become a baseline for a longer‑term correction, reshaping investor expectations for AI‑heavy digital‑health companies.